Form 4: LivaNova PLC Director Bianchi Francesco Reports Share Transactions

Director Francesco Bianchi reports acquisition and disposal of LivaNova PLC ordinary shares and restricted stock units.

Summary

• On June 15, 2024, Director Francesco Bianchi acquired 2,680 ordinary shares of LivaNova PLC upon settlement of restricted stock units (RSUs) at a price of $0.
• On the same day, Bianchi disposed of 585 ordinary shares to satisfy tax liabilities at a price of $52.68 per share.
• Bianchi also acquired 3,416 restricted stock units (RSUs) which vest on June 15, 2025.
• Following these transactions, Bianchi directly owns 10,272 ordinary shares and 3,416 RSUs.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the director is increasing their stake in the company through RSU vesting, indicating confidence. The tax-related disposal is a neutral event.

Positives

• The acquisition of shares through RSU settlement indicates confidence in the company's future performance.
• The grant of additional RSUs vesting in 2025 suggests continued alignment of the director's interests with the company's long-term success.

Negatives

• The disposal of shares to cover tax liabilities, while common, slightly reduces the director's overall shareholding.

Risks

• Future fluctuations in the share price could impact the value of the director's holdings.
• Changes in company performance or market conditions could affect the vesting of the RSUs.

Future Outlook

The director's continued holding of shares and RSUs suggests a positive outlook on the company's future performance.

Industry Context

Director transactions are closely monitored as they can provide insights into management's confidence in the company's prospects within the medical technology industry.

Comparison to Industry Standards

• Director ownership and RSU grants are common practices in publicly traded companies to align management interests with shareholder value.
• Comparable companies in the medical device sector, such as Medtronic or Boston Scientific, also utilize equity-based compensation for their executives and directors.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, reflecting director's confidence.
• Employees may view the RSU grants as a positive sign of the company's commitment to its leadership.

Key Dates